224 related articles for article (PubMed ID: 16354006)
21. Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies.
Cappello B; di Maio C; Iervolino M; Miro A; Calignano A
Drug Dev Ind Pharm; 2009 Jul; 35(7):877-86. PubMed ID: 19466892
[TBL] [Abstract][Full Text] [Related]
22. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
Ozdemir N; Ordu S
Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
[TBL] [Abstract][Full Text] [Related]
23. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems.
Veiga F; Fernandes C; Maincent P
Drug Dev Ind Pharm; 2001 Jul; 27(6):523-32. PubMed ID: 11548859
[TBL] [Abstract][Full Text] [Related]
24. Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis.
Sbârcea L; Udrescu L; Drăgan L; Trandafirescu C; Szabadai Z; Bojiţă M
Pharmazie; 2011 Aug; 66(8):584-9. PubMed ID: 21901980
[TBL] [Abstract][Full Text] [Related]
25. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.
Bandarkar FS; Vavia PR
Drug Dev Ind Pharm; 2011 Nov; 37(11):1318-28. PubMed ID: 21506882
[TBL] [Abstract][Full Text] [Related]
26. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds.
Fernandes CM; Teresa Vieira M; Veiga FJ
Eur J Pharm Sci; 2002 Feb; 15(1):79-88. PubMed ID: 11803134
[TBL] [Abstract][Full Text] [Related]
27. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.
Patil AL; Pore YV; Kuchekar BS; Late SG
Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387
[TBL] [Abstract][Full Text] [Related]
28. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
Fathy M; Sheha M
Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
[TBL] [Abstract][Full Text] [Related]
30. Inclusion complexes of chlorzoxazone with β- and hydroxypropyl-β-cyclodextrin: Characterization, dissolution, and cytotoxicity.
Tang P; Li S; Wang L; Yang H; Yan J; Li H
Carbohydr Polym; 2015 Oct; 131():297-305. PubMed ID: 26256188
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of etoricoxib-beta-cyclodextrin complexes prepared by the kneading method.
Patel HM; Suhagia BN; Shah SA; Rathod IS; Parmar VK
Acta Pharm; 2007 Sep; 57(3):351-9. PubMed ID: 17878114
[TBL] [Abstract][Full Text] [Related]
32. Effect of beta-cyclodextrin and hydroxypropyl beta-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir.
Aleem O; Kuchekar B; Pore Y; Late S
J Pharm Biomed Anal; 2008 Jul; 47(3):535-40. PubMed ID: 18367363
[TBL] [Abstract][Full Text] [Related]
33. Diloxanide furoate binary complexes with β-, methyl-β-, and hydroxypropyl-β-cyclodextrins: inclusion mode, characterization in solution and in solid state and in vitro dissolution studies.
Aloisio C; Longhi M
Pharm Dev Technol; 2018 Sep; 23(7):723-731. PubMed ID: 28758845
[TBL] [Abstract][Full Text] [Related]
34. Sertaconazole/hydroxypropyl-beta-cyclodextrin complexation: isothermal titration calorimetry and solubility approaches.
Rodriguez-Perez AI; Rodriguez-Tenreiro C; Alvarez-Lorenzo C; Taboada P; Concheiro A; Torres-Labandeira JJ
J Pharm Sci; 2006 Aug; 95(8):1751-62. PubMed ID: 16795015
[TBL] [Abstract][Full Text] [Related]
35. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
36. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-beta-cyclodextrin ternary system.
Mura P; Bettinetti GP; Cirri M; Maestrelli F; Sorrenti M; Catenacci L
Eur J Pharm Biopharm; 2005 Jan; 59(1):99-106. PubMed ID: 15567306
[TBL] [Abstract][Full Text] [Related]
37. Preformulation study of the inclusion complex warfarin-beta-cyclodextrin.
Zingone G; Rubessa F
Int J Pharm; 2005 Mar; 291(1-2):3-10. PubMed ID: 15707726
[TBL] [Abstract][Full Text] [Related]
38. Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Wang S; Ding Y; Yao Y
Drug Dev Ind Pharm; 2009 Jul; 35(7):808-13. PubMed ID: 19337873
[TBL] [Abstract][Full Text] [Related]
39. Preparation of olanzapine and methyl-β-cyclodextrin complexes using a single-step, organic solvent-free supercritical fluid process: An approach to enhance the solubility and dissolution properties.
Rudrangi SR; Trivedi V; Mitchell JC; Wicks SR; Alexander BD
Int J Pharm; 2015 Oct; 494(1):408-16. PubMed ID: 26315120
[TBL] [Abstract][Full Text] [Related]
40. Solubility and stability enhancement of atorvastatin by cyclodextrin complexation.
Palem CR; Patel S; Pokharkar VB
PDA J Pharm Sci Technol; 2009; 63(3):217-25. PubMed ID: 20069794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
